59.91
price up icon2.58%   1.58
after-market After Hours: 59.87 -0.04 -0.07%
loading
Novo Nordisk Adr stock is traded at $59.91, with a volume of 11.51M. It is up +2.58% in the last 24 hours and down -22.15% over the past month. With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$58.33
Open:
$59.01
24h Volume:
11.51M
Relative Volume:
1.29
Market Cap:
$293.24B
Revenue:
$42.09B
Net Income/Loss:
$14.65B
P/E Ratio:
18.25
EPS:
3.2833
Net Cash Flow:
$10.11B
1W Performance:
-7.22%
1M Performance:
-22.15%
6M Performance:
-48.63%
1Y Performance:
-52.23%
1-Day Range:
Value
$58.92
$60.18
1-Week Range:
Value
$57.00
$64.41
52-Week Range:
Value
$57.00
$148.15

Novo Nordisk Adr Stock (NVO) Company Profile

Name
Name
Novo Nordisk Adr
Name
Phone
-
Name
Address
-
Name
Employee
76,302
Name
Twitter
@novonordisk
Name
Next Earnings Date
2024-12-06
Name
Latest SEC Filings
Name
NVO's Discussions on Twitter

Compare NVO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
59.91 293.24B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
LLY
Lilly Eli Co
827.54 738.60B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
JNJ
Johnson Johnson
157.75 371.98B 89.33B 21.81B 18.06B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
173.78 312.76B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
111.41 216.19B 51.72B 11.94B 13.81B 5.88

Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-17-25 Downgrade BMO Capital Markets Outperform → Market Perform
Mar-13-25 Upgrade Kepler Hold → Buy
Mar-03-25 Downgrade Stifel Buy → Hold
Feb-12-25 Initiated Morgan Stanley Equal-Weight
Jan-06-25 Upgrade Bernstein Underperform → Mkt Perform
May-30-24 Initiated Goldman Buy
Apr-12-24 Initiated BMO Capital Markets Outperform
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Neutral
Dec-01-23 Initiated Cantor Fitzgerald Overweight
Oct-02-23 Initiated Argus Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-15-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-28-22 Downgrade UBS Neutral → Sell
Jun-27-22 Upgrade Exane BNP Paribas Underperform → Neutral
Jun-07-22 Upgrade JP Morgan Neutral → Overweight
May-31-22 Upgrade Guggenheim Neutral → Buy
Apr-25-22 Upgrade Cowen Market Perform → Outperform
Apr-12-22 Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-16-22 Upgrade Deutsche Bank Hold → Buy
Jan-25-22 Downgrade Liberum Hold → Sell
Dec-20-21 Downgrade JP Morgan Overweight → Neutral
Dec-17-21 Downgrade Deutsche Bank Buy → Hold
Jan-20-21 Downgrade Credit Suisse Outperform → Neutral
Jan-15-21 Initiated Deutsche Bank Buy
Sep-29-20 Initiated Berenberg Hold
Jul-06-20 Downgrade BofA Securities Buy → Neutral
May-11-20 Downgrade UBS Buy → Neutral
May-04-20 Initiated Cowen Market Perform
Mar-16-20 Upgrade BofA/Merrill Neutral → Buy
Jan-03-20 Downgrade Guggenheim Buy → Neutral
Nov-18-19 Upgrade Barclays Equal Weight → Overweight
Sep-17-19 Upgrade Citigroup Neutral → Buy
Aug-30-19 Downgrade Jefferies Hold → Underperform
Jun-20-19 Downgrade Deutsche Bank Buy → Hold
Jun-11-19 Upgrade Barclays Underweight → Equal Weight
Apr-29-19 Upgrade Credit Suisse Neutral → Outperform
Jan-29-19 Initiated Exane BNP Paribas Outperform
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Dec-29-17 Upgrade JP Morgan Underweight → Neutral
Dec-06-17 Upgrade BofA/Merrill Neutral → Buy
Dec-01-17 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-25-17 Downgrade Exane BNP Paribas Outperform → Neutral
Sep-06-17 Upgrade BofA/Merrill Underperform → Neutral
View All

Novo Nordisk Adr Stock (NVO) Latest News

pulisher
08:08 AM

Balance Sheet Breakdown: Novo Nordisk ADR (NVO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX

08:08 AM
pulisher
05:15 AM

Down 60%, Is This Growth Stock Too Cheap to Ignore? - The Motley Fool

05:15 AM
pulisher
Apr 21, 2025

Novo Nordisk ADR (NVO) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com

Apr 21, 2025
pulisher
Apr 17, 2025

European ADRs Rise As Prudential And BP Lead The Pack - Finimize

Apr 17, 2025
pulisher
Apr 17, 2025

NVO Stock Quote Price and Forecast - CNN

Apr 17, 2025
pulisher
Apr 14, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - marketscreener.com

Apr 14, 2025
pulisher
Apr 09, 2025

Is Novo Nordisk Stock a Buy After its Collapse? - Morningstar

Apr 09, 2025
pulisher
Apr 08, 2025

Eli Lilly and Novo Nordisk: Obesity Drug Coverage in Medicare Not a Straight Path - Morningstar

Apr 08, 2025
pulisher
Mar 28, 2025

Is Novo Nordisk (NVO) the Best ADR Stock to Buy According to Hedge Funds? - Insider Monkey

Mar 28, 2025
pulisher
Mar 28, 2025

Novo Nordisk’s $2B deal for obesity drug a strategic game-changer for US pharmaceutical market - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

Why Novo Nordisk Stock Dipped on Thursday - Yahoo Finance

Mar 27, 2025
pulisher
Mar 15, 2025

Novo Nordis Share Price | NYSE: NVO Stock - Investing.com UK

Mar 15, 2025
pulisher
Mar 13, 2025

NOVO_B Stock Price and Chart — OMXCOP:NOVO_B - TradingView

Mar 13, 2025
pulisher
Mar 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/SNVO - Finansavisen

Mar 11, 2025
pulisher
Mar 10, 2025

Novo Nordisk shares plunge after obesity drug trial - The Irish Independent

Mar 10, 2025
pulisher
Mar 07, 2025

Novo Nordisk AS (NVO) Stock Price, Trades & News - GuruFocus.com

Mar 07, 2025
pulisher
Mar 06, 2025

Novo Nordisk A/S Sponsored ADR Class B to Host Earnings Call - ACCESS Newswire

Mar 06, 2025
pulisher
Mar 04, 2025

META_TITLE_QUOTE - Yahoo Finance

Mar 04, 2025
pulisher
Mar 03, 2025

Repare Surprises On Earnings; California Resources Falls Short - Evrim Ağacı

Mar 03, 2025
pulisher
Mar 03, 2025

Why weight-loss drugs are the top target of Medicare price negotiations - Equities News

Mar 03, 2025

Novo Nordisk Adr Stock (NVO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$173.78
price up icon 2.36%
drug_manufacturers_general NVS
$111.41
price up icon 0.77%
drug_manufacturers_general JNJ
$157.75
price up icon 0.54%
drug_manufacturers_general MRK
$78.97
price up icon 1.24%
$278.40
price up icon 1.69%
Cap:     |  Volume (24h):